Letter by Jin-shan and Xue-bin Regarding Article, “Effect of Aggressive Blood Pressure Control on the Recurrence of Atrial Fibrillation After Catheter Ablation: A Randomized, Open-Label Clinical Trial (SMAC-AF [Substrate Modification With Aggressive Blood Pressure Control])”

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
We read with great interest the article by Parkash et al1 about the effect of aggressive blood pressure control on the recurrence of atrial fibrillation after catheter ablation, which shows that aggressive control of blood pressure for a median duration of 3.5 months before catheter ablation and after has no effect on subsequent arrhythmia outcome at the expense of treatment-related hypotension. Does aggressive blood control have a neutral effect on the recurrence of atrial fibrillation after catheter ablation? We have several disagreements. First, before aggressive blood pressure …
American Heart Association Professional?
Log in using your username and password
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
This Issue
Article Tools
- Letter by Jin-shan and Xue-bin Regarding Article, “Effect of Aggressive Blood Pressure Control on the Recurrence of Atrial Fibrillation After Catheter Ablation: A Randomized, Open-Label Clinical Trial (SMAC-AF [Substrate Modification With Aggressive Blood Pressure Control])”He Jin-shan and Li Xue-binCirculation. 2017;136:1269-1270, originally published September 25, 2017https://doi.org/10.1161/CIRCULATIONAHA.117.030017
Citation Manager Formats
Share this Article
- Letter by Jin-shan and Xue-bin Regarding Article, “Effect of Aggressive Blood Pressure Control on the Recurrence of Atrial Fibrillation After Catheter Ablation: A Randomized, Open-Label Clinical Trial (SMAC-AF [Substrate Modification With Aggressive Blood Pressure Control])”He Jin-shan and Li Xue-binCirculation. 2017;136:1269-1270, originally published September 25, 2017https://doi.org/10.1161/CIRCULATIONAHA.117.030017







